Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06060977 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants
A Phase 1 study of Alopecia Areata (AA), sponsored by Inmagene.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 17
- Study locations
NCT06060977 is a Phase 1 study of Alopecia Areata (AA) that has completed, run by Inmagene. The registered enrollment target is 29 participants. The trial reports 17 study locations across 13 states.
The verdict
NCT06060977, a Phase 1 study of Alopecia Areata (AA), has completed, sponsored by Inmagene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 17
- Study locations
Study Summary
The primary objective of the study is to evaluate the safety of IMG-007 in adults with Alopecia Areata.
Conditions Studied
Interventions
- DRUG IMG-007
Study Locations (17)
Ontario
- SimcoMed Health Ltd. - Barrie
- Skin Health - Cobourg
- Guelph Dermatology Research - Guelph
- Research Toronto - Toronto
Indiana
- Dawes Fretzin Clinical Resarch Group, LLC - Indianapolis
- Options Research Group - West Lafayette
Arkansas
- Northwest Arkansas Clinical Trials Center, PLLC/ Hull Dermatology P.A. - Rogers
California
- Torrance Clinical Research Institute Inc. - Lomita
Florida
- Alliance Clinical Research of Tampa - Tampa
Massachusetts
- Lahey Hospital & Medical Center - Burlington
Michigan
- Great Lakes Research Group Inc. - Bay City
Nevada
- Skin Cancer and Dermatology Institute - Reno
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2023-09-25 |
| Est. Completion | 2025-01-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06060977
The ClinicalTrials.gov registry entry for NCT06060977 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inmagene, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alopecia Areata (AA) appearing as the primary indexed condition, and to 1 intervention - of which IMG-007 is the first listed.
NCT06060977 reports 17 study locations spanning 13 distinct geographic areas - top geographies include Ontario, Indiana, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06060977 about?
NCT06060977 is a clinical study titled "A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants". The primary objective of the study is to evaluate the safety of IMG-007 in adults with Alopecia Areata.
What is the current status of trial NCT06060977?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2023-09-25. Estimated completion is 2025-01-14.
What conditions does trial NCT06060977 study?
This clinical trial studies the following conditions: Alopecia Areata (AA).
What interventions are being tested in trial NCT06060977?
The interventions under investigation include: IMG-007 (DRUG).
Who is sponsoring clinical trial NCT06060977?
This trial is sponsored by Inmagene, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06060977 being conducted?
This trial has 17 study locations across Arkansas, California, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alopecia Areata (AA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.